Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00288067 · ClinicalTrials.gov registry record · Phase 1
Fenretinide and Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Terminated
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT00288067: Clinical Trial Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00288067 is a Phase 1 study that was terminated before completion, run by National Cancer Institute (NCI). The registered enrollment target is 32 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00288067, a Phase 1 study, was terminated before completion, sponsored by National Cancer Institute (NCI).
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
This phase I/II trial is studying the side effects and best dose of fenretinide and to see how well it works when given together with rituximab in treating patients with B-cell non-Hodgkin lymphoma. Drugs used in chemotherapy, such as fenretinide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some find cancer cells and kill them or carry cancer-killing substances to them. Others interfere with the ability of cancer cells to grow and spread. Giving fenretinide together with rituximab may kill more cancer cells.
Interventions
- DRUG rituximab
- DRUG fenretinide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2005-10 |
| Est. Completion | 2013-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00288067
The ClinicalTrials.gov registry entry for NCT00288067 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which rituximab is the first listed.
NCT00288067 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00288067 about?
NCT00288067 is a clinical study titled "Fenretinide and Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma". This phase I/II trial is studying the side effects and best dose of fenretinide and to see how well it works when given together with rituximab in treating patients with B-cell non-Hodgkin lymphoma. Drugs used in chemotherapy, such as fenretinide, work in different ways to stop the growth of cancer ...
What is the current status of trial NCT00288067?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2005-10. Estimated completion is 2013-07.
What interventions are being tested in trial NCT00288067?
The interventions under investigation include: rituximab (DRUG), fenretinide (DRUG).
Who is sponsoring clinical trial NCT00288067?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.